Abbvie Inc (ABBV)

$229.89 +1.10 (0.48%)
Market Cap 404.36B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.12
Forward PE 21.40
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 1,744,900
Avg Vol 5,748,020
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 91%
Beta 0.36
Analysts Strong Sell
Price Target $245.84

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
1iquid
1iquid Dec. 25 at 5:31 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $240 Calls Scale in: $19.14- $23.39 Scale out: $74.42-$127.57 Profit Potential : 164% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 9:07 PM
Enter: $ABBV Calls Strike Price: $240 Expiry Date: JAN 16 2026 Buy in Price: $1.25 - $1.75 Sell Price: $2.54 Profit : +103% (Turn every $1 into $2.03) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Evonsobhy
Evonsobhy Dec. 24 at 4:35 PM
$PLTR $ASML $BAC $ABBV $NFLX I know that!
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 24 at 4:00 PM
$SLS 2nd Day in a Row, Cracked the 52 week High -- you see what's happening - and it is exactly what you would like to see ahead of the Phase 3 Results. - the Share Price will Continue Climbing Until it absolutely Launches PSA: Industry Players $ABBV $BMY $RHHBY KNOW precisely how their Drugs - AzaVEN - Best Available Treatment BAT perform for the SLS Phase 3 Control Arm Patients - 2 AzaVEN Phase 3 Trials Have recently FAILED - AML Maintenance Trials VIALE-M - AML First Remission Maintenance Trial TERMINATED due to Toxicity VIALE-T - AML Post Transplant Maintenance Trial Terminated due to Toxicity. --- and SLS Mcap is Now Up 500% Since the IDMC Unblinded the INTERIM ALL Pooled Phase 3 MOS and IR DATA. Institutional Funds are up to 154 last report (its more now), up from just 39, when the IDMC Unblinded ActualPhase 3 MOS DATA. Call to Put ratio is 99.99 to 0.01 SLS had 13M in Cash its Now $74M Runway into 2028.
0 · Reply
CocoaContract
CocoaContract Dec. 24 at 3:26 PM
$ABBV Strategic optionality narrows unless proof that pricing power can persist through normalization phases, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 24 at 9:06 AM
Top 5 US Healthcare Stocks By Market Value $LLY $MRK $UNH $JNJ $ABBV https://stocktwits.com/news/equity/markets/top-5-us-healthcare-stocks-by-market-value/cLeso9WREHH
0 · Reply
Longbuy1
Longbuy1 Dec. 23 at 5:45 PM
$SLS everyday man, shorts get slaughtered, 10% easy. Same shit for the half day tomorrow. Then we might get a PR EOD Friday. But we'll already be at 3.30. $PFE $MRK $ABBV wants our AML cancer cure. (3 year survival right now, 5 year is when docs start throwing the cure word out there.) For patients that usually live 6 months with the crap that's out there for AML. Plus biotech is hot.
1 · Reply
biolover
biolover Dec. 23 at 3:59 PM
$VKTX well they are different peptides. So u can’t do mg for mg But like the sc dual agonists are better tolerated and more effective than single GLP1 like $NVO sema , the oral dual agonist will be more effective and better tolerated. Viking needed to make pills smaller and they worked on that per CEO. Novo CEO should partner with Viking ( not for sale ) and he can easily catch up to $LLY in 2-3 years.. there is oral amylin coming from Viking as well Amgen , Roche and Pfizer don’t have competitive drugs. If $ABBV or $BMY gets to Viking drugs first , good luck to Doustdar
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 3:59 PM
$ABBV vs. $AZN — pharma giants, very different paths ahead 💊 Both AbbVie and AstraZeneca bring blockbuster drugs and deep pipelines, but their growth trajectories, risk profiles, and strategic priorities are now clearly diverging. See which pharma stock looks like the better bet right now 👉 https://www.zacks.com/stock/news/2808056/abbv-vs-azn-which-pharma-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2808056-teaser-25991&ADID=SYND_STOCKTWITS_TWEET_2_2808056_TEASER_25991
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 2:59 PM
$ABBV vs. $AZN: Which Pharma Giant Offers More Value? 💊 🔹 $ABBV's growth is driven by Skyrizi & Rinvoq, with its aggressive M&A strategy strengthening its long-term pipeline but weighing on near-term earnings. 🔹 $AZN boasts a diversified portfolio across multiple therapeutic areas, showcasing a balanced growth profile. Which stock is the better pick for your portfolio? Full analysis here 👉 https://www.zacks.com/stock/news/2808056/abbv-vs-azn-which-pharma-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2808056-body-25990&ADID=SYND_STOCKTWITS_TWEET_2_2808056_BODY_25990
0 · Reply
Latest News on ABBV
Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 5 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 7 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

Dec 17, 2025, 2:17 PM EST - 7 days ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Dec 14, 2025, 11:30 PM EST - 10 days ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 14 days ago

AbbVie: Unique Mix Of Growth And Value

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 8, 2025, 1:30 AM EST - 17 days ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 4:53 PM EST - 21 days ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 2, 2025, 8:15 AM EST - 22 days ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Dec 1, 2025, 5:55 AM EST - 23 days ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 25 days ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 28, 2025, 7:01 AM EST - 26 days ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 25, 2025, 9:30 AM EST - 4 weeks ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 4 weeks ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 12:47 PM EST - 5 weeks ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

It's Best Time In 10 Years To Lock In Income: Our Picks

Nov 18, 2025, 9:00 AM EST - 5 weeks ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 5 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 4:31 PM EST - 5 weeks ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 5 weeks ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 13, 2025, 8:30 AM EST - 5 weeks ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 6 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 6 weeks ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 12, 2025, 8:30 AM EST - 6 weeks ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 6 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 6 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 7 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

Nov 1, 2025, 11:15 PM EDT - 7 weeks ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 7 weeks ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 7 weeks ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 11:47 AM EDT - 7 weeks ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 7 weeks ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 7 weeks ago

AbbVie Lifts Profit Outlook as Sales Rise

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 8:20 AM EDT - 7 weeks ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:54 AM EDT - 7 weeks ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 7 weeks ago

AbbVie Reports Third-Quarter 2025 Financial Results

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Oct 29, 2025, 5:00 PM EDT - 2 months ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Oct 29, 2025, 8:11 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 2 months ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH

AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 2 months ago

AbbVie: Deep Discount Before Earnings

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

Oct 28, 2025, 10:40 AM EDT - 2 months ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

GILD LLY MRK

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

Oct 21, 2025, 2:27 PM EDT - 2 months ago

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

APTV PANW QCOM

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Oct 21, 2025, 8:00 AM EDT - 2 months ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

Oct 20, 2025, 8:12 AM EDT - 2 months ago

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

Oct 20, 2025, 8:00 AM EDT - 2 months ago

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

Oct 17, 2025, 4:34 PM EDT - 2 months ago

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Oct 17, 2025, 9:00 AM EDT - 2 months ago

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

Oct 13, 2025, 1:28 PM EDT - 2 months ago

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

AMZN DDOG TSLX

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Oct 13, 2025, 10:57 AM EDT - 2 months ago

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Oct 13, 2025, 7:15 AM EDT - 2 months ago

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

Oct 9, 2025, 8:00 AM EDT - 2 months ago

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 2 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ALVO AMGN ARKG AZN BIIB BMY GILD

1iquid
1iquid Dec. 25 at 5:31 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $240 Calls Scale in: $19.14- $23.39 Scale out: $74.42-$127.57 Profit Potential : 164% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 9:07 PM
Enter: $ABBV Calls Strike Price: $240 Expiry Date: JAN 16 2026 Buy in Price: $1.25 - $1.75 Sell Price: $2.54 Profit : +103% (Turn every $1 into $2.03) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Evonsobhy
Evonsobhy Dec. 24 at 4:35 PM
$PLTR $ASML $BAC $ABBV $NFLX I know that!
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 24 at 4:00 PM
$SLS 2nd Day in a Row, Cracked the 52 week High -- you see what's happening - and it is exactly what you would like to see ahead of the Phase 3 Results. - the Share Price will Continue Climbing Until it absolutely Launches PSA: Industry Players $ABBV $BMY $RHHBY KNOW precisely how their Drugs - AzaVEN - Best Available Treatment BAT perform for the SLS Phase 3 Control Arm Patients - 2 AzaVEN Phase 3 Trials Have recently FAILED - AML Maintenance Trials VIALE-M - AML First Remission Maintenance Trial TERMINATED due to Toxicity VIALE-T - AML Post Transplant Maintenance Trial Terminated due to Toxicity. --- and SLS Mcap is Now Up 500% Since the IDMC Unblinded the INTERIM ALL Pooled Phase 3 MOS and IR DATA. Institutional Funds are up to 154 last report (its more now), up from just 39, when the IDMC Unblinded ActualPhase 3 MOS DATA. Call to Put ratio is 99.99 to 0.01 SLS had 13M in Cash its Now $74M Runway into 2028.
0 · Reply
CocoaContract
CocoaContract Dec. 24 at 3:26 PM
$ABBV Strategic optionality narrows unless proof that pricing power can persist through normalization phases, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 24 at 9:06 AM
Top 5 US Healthcare Stocks By Market Value $LLY $MRK $UNH $JNJ $ABBV https://stocktwits.com/news/equity/markets/top-5-us-healthcare-stocks-by-market-value/cLeso9WREHH
0 · Reply
Longbuy1
Longbuy1 Dec. 23 at 5:45 PM
$SLS everyday man, shorts get slaughtered, 10% easy. Same shit for the half day tomorrow. Then we might get a PR EOD Friday. But we'll already be at 3.30. $PFE $MRK $ABBV wants our AML cancer cure. (3 year survival right now, 5 year is when docs start throwing the cure word out there.) For patients that usually live 6 months with the crap that's out there for AML. Plus biotech is hot.
1 · Reply
biolover
biolover Dec. 23 at 3:59 PM
$VKTX well they are different peptides. So u can’t do mg for mg But like the sc dual agonists are better tolerated and more effective than single GLP1 like $NVO sema , the oral dual agonist will be more effective and better tolerated. Viking needed to make pills smaller and they worked on that per CEO. Novo CEO should partner with Viking ( not for sale ) and he can easily catch up to $LLY in 2-3 years.. there is oral amylin coming from Viking as well Amgen , Roche and Pfizer don’t have competitive drugs. If $ABBV or $BMY gets to Viking drugs first , good luck to Doustdar
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 3:59 PM
$ABBV vs. $AZN — pharma giants, very different paths ahead 💊 Both AbbVie and AstraZeneca bring blockbuster drugs and deep pipelines, but their growth trajectories, risk profiles, and strategic priorities are now clearly diverging. See which pharma stock looks like the better bet right now 👉 https://www.zacks.com/stock/news/2808056/abbv-vs-azn-which-pharma-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2808056-teaser-25991&ADID=SYND_STOCKTWITS_TWEET_2_2808056_TEASER_25991
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 2:59 PM
$ABBV vs. $AZN: Which Pharma Giant Offers More Value? 💊 🔹 $ABBV's growth is driven by Skyrizi & Rinvoq, with its aggressive M&A strategy strengthening its long-term pipeline but weighing on near-term earnings. 🔹 $AZN boasts a diversified portfolio across multiple therapeutic areas, showcasing a balanced growth profile. Which stock is the better pick for your portfolio? Full analysis here 👉 https://www.zacks.com/stock/news/2808056/abbv-vs-azn-which-pharma-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2808056-body-25990&ADID=SYND_STOCKTWITS_TWEET_2_2808056_BODY_25990
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 23 at 3:17 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 16 2026 Buy in Price: $4.30 - $4.60 Sell Price: $6.84 Profit : +59% (Turn every $1 into $1.59) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
KenFaulkenberry
KenFaulkenberry Dec. 23 at 2:14 AM
$ABBV Abbvie (ABBV) Stock Analysis (Dividend King) AbbVie is a global, research-based biopharmaceutical company engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of AbbVie (ABBV)? https://dividendvaluebuilder.com/abbvie-abbv-dividend-stock-analysis/
0 · Reply
TalkMarkets
TalkMarkets Dec. 22 at 10:58 PM
Health Science Stocks: Recent Picks And Year End Trading… Green Screen Day Alert $REGN $GILD $IHI $XBI $ABBV https://talkmarkets.com/content/etfs/health-science-stocks-recent-picks-and-year-end-trading-green-screen-day-alert?post=546243
0 · Reply
Longbuy1
Longbuy1 Dec. 22 at 7:30 PM
$SLS if we try hard enough we can turn this into a meme stock $GME. Plus a AML cancer biotech that gets bought out by $PFE or $$ABBV for 10 billion or 45$ a share.
3 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Dec. 22 at 1:59 PM
$ARWR Named Top Pick at Piper 2026 $ABBV $AMGN $TEVA
0 · Reply
GoodTidings
GoodTidings Dec. 22 at 1:41 PM
$SLS I understand that $PFE is somehow in the picture... That extends the favourable $ABBV and the other player $MRK 🤔🤔🤔
0 · Reply
Longbuy1
Longbuy1 Dec. 21 at 5:19 PM
$SLS Lol, take off your stop losses, shorts are going to try to get your shares cheap. (Every morning there is a drop) Phase 3 GPS readout is any day. The data, which almost all us expect to be good, combined with the better than expected SLS phase 2 trial results; so good the FDA personally requested a more controlled study with more recently diagnosed AML patients to enroll. 217M float, warrants are done and exercised, this is going to go into a a bidding war between $PFE $ABBV $MRK 10 billion? 25 billion who knows? Angelo cancelled his meeting with Pfizer CEO. Maybe there's already a buyer. You can take your 35% gain or wait for the 1000%.
1 · Reply
1iquid
1iquid Dec. 21 at 5:53 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $21.70- $26.52 Scale out: $84.39-$144.68 Profit Potential : 136% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 21 at 2:21 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 09 2026 Buy in Price: $3.75 - $3.80 Sell Price: $6.00 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
MetalinMaybach
MetalinMaybach Dec. 20 at 7:23 PM
$ABBV NGENF is getting ready to list with Nasdaq very soon. This is mainly focused in the SCI space but has applications in other CNS diseases as shown in preclinical trials. If it lists this will be a good opportunity to capitalize on benefits of more exposure.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 20 at 7:22 PM
$SLS $ABBV 23% Fatal Adverse Reactions - FATAL - and 83% Rate of Serious Adverse reactions in Newly Diagnosed AML Patients. Abbvie terminated the VEN AZA VIALE-M and the VIALE-T Maintenance trials for First Remission and Post Stem Cell Transplant patients - due to toxicity. The Toxicity is MORE Harmful to AML Second Remission Patients. VEN+AZA - BAT for the REGAL trial is not effective maintenance treatment, for post R/R AML patients obtaining a Second Remission (CR2) and who are Ineligible for a transplant operation. VEN AZA is Toxic. BAT for REGAL Control Patient's Toxic - its important as people consider what BAT is and isn't.
0 · Reply
1iquid
1iquid Dec. 20 at 5:56 AM
OptionWizards Tip (education only): Start with defined-risk strategies like vertical spreads on stocks such as PLTR, COST, or ABBV to help manage potential… $PLTR $COST $ABBV Not financial advice.
0 · Reply